0000950170-24-054694.txt : 20240507 0000950170-24-054694.hdr.sgml : 20240507 20240507170009 ACCESSION NUMBER: 0000950170-24-054694 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240503 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Magovcevic-Liebisch Ivana CENTRAL INDEX KEY: 0001279281 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41200 FILM NUMBER: 24922976 MAIL ADDRESS: STREET 1: 300 TECHNOLOGY SQUARE STREET 2: 8TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER NAME: FORMER CONFORMED NAME: Magovcevic Ivana DATE OF NAME CHANGE: 20040503 FORMER NAME: FORMER CONFORMED NAME: MARAVIC MAGOVCEVIC IVANA DATE OF NAME CHANGE: 20040209 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vigil Neuroscience, Inc. CENTRAL INDEX KEY: 0001827087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FORGE ROAD STREET 2: SUITE 700 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-254-4445 MAIL ADDRESS: STREET 1: 100 FORGE ROAD STREET 2: SUITE 700 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 ownership.xml 4 X0508 4 2024-05-03 0001827087 Vigil Neuroscience, Inc. VIGL 0001279281 Magovcevic-Liebisch Ivana VIGIL NEUROSCIENCE, INC. 100 FORGE ROAD, SUITE 700 WATERTOWN MA 02472 true true false false President and CEO false Stock Option Award (Right to Buy) 16.13 2024-05-03 4 D false 282000 0.00 D 2032-03-01 Common Stock 282000 0 D Stock Option Award (Right to Buy) 3.03 2024-05-03 4 A false 282000 0.00 A 2032-03-01 Common Stock 282000 282000 D Stock Option Award (Right to Buy) 11.87 2024-05-03 4 D false 370000 0.00 D 2033-03-01 Common Stock 370000 0 D Stock Option Award (Right to Buy) 3.03 2024-05-03 4 A false 370000 0.00 A 2033-03-01 Common Stock 370000 370000 D On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable in forty-eight (48) equal monthly installments, with the first installment having vested on April 1, 2022. The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan), (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability, and (iv) the termination of the Reporting Person's Service Relationship for Good Reason (as defined in the Reporting Person's employment agreement). This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable in forty-eight (48) equal monthly installments, with the first installment having vested on April 1, 2023. /s/ Christopher Verni, Attorney-in-Fact 2024-05-07